BioCentury
ARTICLE | Clinical News

Aptosyn exisulind: Phase III data

June 14, 2004 7:00 AM UTC

In a U.S. Phase III trial in 610 patients, Aptosyn plus Taxotere missed the primary endpoint of improving overall survival vs. Taxotere plus placebo. Median survival was 6.9 months for both treatment...